Nervous System/Brain Cancer Panel, NGS
Malignant tumors of the brain and spinal cord including the meninges, pituitary gland, pineal gland, and nerves constitute the Central nervous system cancers. Mutations of over 15 genes are known to be responsible for these cancers. Most of mutations have an autosomal dominant inheritance pattern and very few are inherited in an autosomal recessive pattern. Central Nervous System cancers are diagnosed primarily on histopathological features. However, morphologically similar tumors show variable molecular markers and consequently have different prognosis and management strategies. Following genes are implicated in pathogenesis of CNS cancers: HRAS, MEN1, MLH1, PRKAR1A, PTCH1, PTEN, SMARCA4, SMARCB1, ALK, APC, ATM, DICER1, EPCAM, SMARCE1, PHOX2B, PMS2, POT1, SUFU, TP53, TSC1, TSC2, VHL MSH2, MSH6.
Panel Components
Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate for most common variants within genes: HRAS, MEN1, MLH1, PRKAR1A, PTCH1, PTEN, SMARCA4, SMARCB1, ALK, APC, ATM, DICER1, EPCAM, SMARCE1, PHOX2B, PMS2, POT1, SUFU, TP53, TSC1, TSC2, VHL MSH2, MSH6.
- As an aid in diagnosis of CNS cancers
- As an aid in classification of CNS cancers
- In understanding prognosis of CNS cancers
- Disease and therapy management
Negative for mutation analyze (No reportable variants were identified)
Whole blood (EDTA), Formalin-Fixed, Paraffin-Embedded Tissue (FFPE).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- J Pathol Transl Med. 2017 May; 51(3): 205–223. [PMID: 28535583]
- J Korean Neurosurg Soc. 2010 Aug; 48(2): 145–152. [PMID: 20856664]
- N Engl J Med. 2015 Dec 25. [PMID: 26061751]
- Cell Mol Life Sci. 2014; 71(20): 4007–4026. [PMID: 25008045]
- Radiographics. 2017 Jan-Feb;37(1):258-280 [PMID: 27911673]